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We report a case of a female patient with alveolar echinococcosis (AE) who presented with progressive pulmonary
and hepatic lesions and had a fatal outcome. AE affecting the liver, the lungs and the brain had been diagnosed 20
years ago and treated successfully with albendazole and stereotactic gamma knife therapy. Due to severe hair loss
albendazole was stopped 14 years before presentation. Lesions had remained stable in imaging studies for at least
11 years, but then had started to progress. Lifelong anthelmintic maintenance therapy and regular follow-up may
therefore be crucial in order to prevent such a dramatic clinical course.
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A 49-year-old Swiss female was admitted in December
2012 with progressive dyspnoea and bilateral peripheral
oedema to the Division of Pulmonology, University Hos-
pital of Graz, Austria. Following the diagnosis of alveolar
echinococcosis (AE) affecting the liver, the lungs and the
brain, in 1992 treatment with mebendazole plus inter-
feron gamma was initiated [1]. Then, in 1994, therapy
was switched to albendazole and stereotactic gamma
knife therapy due to progressive cerebral lesions. As the
patient remained stable with minimal neurological
symptoms we concluded that gamma knife radiosurgery
may be an alternative for patients with cerebral AE for
whom surgery is not possible [2].
After four years of stable disease anthelmintic treat-
ment was stopped in 1998 due to severe hair loss, which
was mentally unbearable for the patient. The patient did
not receive anthelmintic treatment for the following 14
years. Until September 2009 the patient was followed-up
monthly and then annually with pulmonary, hepatic and
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reproduction in any medium, provided the orstudies. The patient had no further complaints. After
2009 the patient was, however, lost to follow-up, and no
further imaging studies were performed at our centre.
At admission in 2012 computed tomography revealed
a dramatic progress of the known pulmonary bilobular
lesions when compared to 2009 and a large partially
calcified hepatic lesion with complete obstruction of
the inferior vena cava, while cerebral lesions had
remained stable in magnetic resonance imaging of
the brain. According to the recommendations of the
WHO-Informal Working Group on Echinococcosis,
albendazole (400 mg b.i.d.) was initiated [3-5]. After four
days the patient developed severe respiratory failure and
was intubated. Liposomal amphotericin B (3 mg/kg
daily) was added as anthelmintic salvage therapy. Despite
using all technical facilities the patient died of respira-
tory insufficiency after 20 days at the intensive care unit.
Autopsy confirmed cystic, partly calcified and centrally
necrotized infiltrations of both lungs (Figure 1), the liver
and the brain. Histology of the brain, the lung and the
liver revealed large cystic lesions with eosinophilic brood
capsules, scolices and daughter cysts. The cysts were
surrounded by dense fibrovascular tissue with chronic
inflammatory cells and showed a varying degree of
calcification.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Macroscopic appearance of the affected lung.
Cystic lesions are indicated by the arrow, the black asterices indicate
calcified and the white asterices indicate hemorrhagic
necrotic lesions.
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Caused by Echinococcus multilocularis, AE is endemic in
Central and Eastern Europe, the Near East, Russia,
China, and Japan [6,7]. Increasing annual incidence rates
are reported from a number of countries, including
Austria [8]. After an asymptomatic incubation period,
patients typically develop a slowly progressive tumor-like
destructive liver disease. Since the introduction of
mebendazole in 1977 and albendazole in 1992 life ex-
pectancy has dramatically improved [9]. Ammann and
colleagues previously reported a 67-year-old male pa-
tient with non-resectable AE of the liver who had been
continuously treated for 13 years with mebendazole until
he died due to a condition unrelated to AE. Autopsy
findings were suggestive of a parasitocidal efficacy of
mebendazole treatment [10]. The fact that pulmonary
and hepatic lesions remained stable for at least 11 years
in our patient, even though anthelmintic therapy was
discontinued, suggests that intensified treatment has a
huge impact on Echinococcus multilocularis. The follow-
ing progression of AE with the fatal outcome, however,
stands in contrast to a potential curative efficacy. To
prevent such dramatic clinical courses, lifelong anthel-
mintic maintenance therapy and lifelong regular follow-
up seems to be crucial [11].Abbreviation
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